<DOC>
	<DOCNO>NCT00483509</DOCNO>
	<brief_summary>The main objective trial document progression free survival ( PFS ) advance metastatic SCLC patient affect advanced metastatic small cell lung carcinoma ( SCLC ) previously treat least one therapeutic regimen</brief_summary>
	<brief_title>Study NGR-hTNF Combination With Doxorubicin Patients Affected Metastatic Small Cell Lung Carcinoma</brief_title>
	<detailed_description>This phase II , open-label , non-randomized study conduct patient affect advanced metastatic SCLC , previously treat least one therapeutic regimen , conduct use Simon 's two-stage design method .</detailed_description>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<criteria>Patients ≥ 18 year affect SCLC previously treat least one therapeutic regimen ( include doxorubicin ) . However , case patient already pretreated doxorubicin , previous cumulative dose doxorubicin &lt; 300 mg/m^2 recommend current treatment stop maximum cumulative dose doxorubicin 550 mg/m^2 reach . Cytology histology confirm SCLC first diagnosis ( patient recurrent disease require confirmatory biopsy eligible ) Measurable disease , define ≥ 1 unidimensional measurable lesion ≥ 20 mm conventional technique ≥ 10 mm CT scan accord RECIST criterion ECOG Performance status 0 2 Adequate baseline bone marrow , hepatic renal function , define follow : Neutrophils &gt; 1.5 x 10^9/L platelet &gt; 100 x 10^9/L Bilirubin &lt; 1.5 x ULN AST and/or ALT &lt; 2.5 x ULN absence liver metastasis AST and/or ALT &lt; 5 x ULN presence liver metastasis Serum creatinine &lt; 1.5 x ULN Absence condition hypervolaemia consequence ( e.g . increase stroke volume , elevate blood pressure ) haemodilution could represent risk patient ( reference appendix `` Technical data sheet human albumin '' ) Normal cardiac function ( LVEF ≥ 55 % ) absence uncontrolled hypertension Patients may prior therapy provide follow condition meet : Chemotherapy , radiation therapy , hormonal therapy immunotherapy : washout period 28 day start treatment Surgery : washout period 14 day start treatment Patients must give write informed consent participate study Concurrent anticancer therapy Patients may receive investigational agent study Patients myocardial infarction within last six ( 6 ) month , unstable angina , New York Heart Association ( NYHA ) grade II great congestive heart failure , serious cardiac arrhythmia require medication Uncontrolled hypertension Prolonged QTc interval ( congenital acquire ) Patient significant peripheral vascular disease Previous sign cardiotoxicity doxorubicin related Clinical sign CNS involvement Patients active uncontrolled systemic disease/infections serious illness medical condition , incompatible protocol Known hypersensitivity/allergic reaction contraindication human albumin preparation excipients Known hypersensitivity/allergic reaction contraindication anthracyclines Any psychological , familial , sociological geographical condition potentially hamper compliance study protocol Pregnancy lactation . Patients male female reproductive potential ( i.e . menopausal le 1year surgically sterilize ) must practice effective contraceptive measure throughout study . Women childbearing potential must provide negative pregnancy test ( serum urine ) within 14 day prior registration .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>NGR-hTNF</keyword>
	<keyword>SCLC</keyword>
</DOC>